Skip to the cards
Filed
Source
Laura Varley
Loans
526

Isomorphic Labs and MSD team up on AI-led cancer drug discovery

INNOVATION Isomorphic Labs and MSD team up on AI-led cancer drug discovery by Laura Varley 20 Nov 2026 Save article Image: © Fahroni/Stock.adobe.com The partnership will see both organisations coll...

Isomorphic Labs and MSD team up on AI-led cancer drug discovery

Isomorphic Labs and MSD team up on AI-led cancer drug discovery

20 Nov 2026

Image: © Fahroni/Stock.adobe.com

The partnership will see both organisations collaborate on oncology drug therapies designed to target small molecules.

Alphabet’s Isomorphic Labs and MSD are set to collaborate on a research project that will combine Isomorphic Labs’ AI technology with MSD’s data resources and experience. 

The partnership will aim to “discover therapeutic small molecule candidates against an oncology target of strategic importance”. That is to say, Isomorphic Lab’ and MSD will work together to find potential new cancer drugs aimed at a prioritised target.

As part of the collaboration Isomorphic Labs will use in silico prediction, which is the use of computational or computer-simulated experiments used in drug discovery to deliver drug molecule designs. The company will apply MSD’s datasets to its own drug design engine (IsoDDE).

MSD involvement will include pre-clinical and clinical development, manufacturing and bringing any resulting medicines to market.

Among the terms of the partnership agreement, Isomorphic Labs will receive an upfront payment from MSD and will also be eligible for payments based on the achievement of specified research, development, regulatory and commercial milestones. 

Earlier in the week Isomorphic Labs announced that the company had raised $5bn in Series C funding. 

The round was co-led by Greenoaks and Sequoia Capital, alongside Andreessen Horowitz, several other new investors and a significant investment from Alphabet. The round also included participation from existing investors Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund.

Commenting on the partnership with MSD, Sarah Skerratt, the chief research officer at Isomorphic Labs, said: “Through this collaboration with MSD, we will apply our world-leading drug design engine to unlock significant discovery progress.

“By leveraging the generative and predictive power of the IsoDDE to address this challenging programme, this collaboration highlights our companies’ shared commitment to innovation for the benefit of patient populations with unmet needs.”

George Addona, the senior vice-president and head of discovery, preclinical development and translational medicine at MSD Research Laboratories, said: “The key to successfully leveraging AI/ML for molecular invention lies in close coordination of wet-lab and dry-lab functions.

“By combining MSD’s substantial internal data capabilities and discovery expertise with Isomorphic Labs’ powerful modelling and compute capabilities, we aim to identify new ways to design and create better candidates faster.”

Don’t miss out on the knowledge you need to succeed. Sign up for the Daily Brief, Silicon Republic’s digest of need-to-know sci-tech news.

Laura Varley is the Careers editor for Silicon Republic

[email protected]


Source: Laura Varley · www.siliconrepublic.com

Filed alongside